An overview of dapagliflozin (FORXIGA®): clinical trials and in-clinic experience
Dapagliflozin (Forxiga) is a sodium glucose co-transporter inhibitor (SGLT2i), a new class of oral type 2 diabetes medication which inhibits renal glucose reabsorption resulting in urinary glucose excretion . The action of dapagliflozin is independent of insulin and does not impair normal endogenous glucose production in response to hypoglycaemia1. In addition to improving glycaemic control, the urinary glucose excretion induced by dapagliflozin is associated with reduction in weight but also contributes to its adverse effect profile which includes genital infections, urinary tract infections and volume depletion1. Dapagliflozin was the first SGLT2i to be approved for use in the management of type 2 diabetes1. It has been registered in Australia as well as in Europe. The objective of this symposium is to provide attendees with a balanced overview of the dapagliflozin clinical trials program and to share the early in-clinic experience with dapagliflozin in Europe.